SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards as the community discusses concerns around declining traffic, margin pressures, and lowered sales outlook, potentially driven by consumer spending habits and pricing. Some traders believe the stock is oversold, presenting a buying opportunity, while others express concerns about the company's current leadership and competitive landscape. Community members are also debating if a change in strategy is needed to better appeal to a broader customer base.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to renewed optimism fueled by raised FY25 EBITDA guidance and a potential short squeeze, with the community actively discussing target prices and the possibility of further upside. A top-line Q3 beat and recent earnings surprise are adding to the positive sentiment. Some traders are closely monitoring the stock's short interest and anticipating a significant price movement.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to upcoming Phase 3 data for its DMD treatment, with investors closely watching for positive results that could lead to FDA approval; community chatter reflects both excitement and apprehension, as the data represents a pivotal moment for the company. Community members also highlight BlackRock's substantial stake in Capricor. Some traders cite the potential for a significant short squeeze based on the stock's high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

Equity

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda in combination with chemoradiotherapy (CRT) for the treatment of advanced-stage cervical cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRK">Merck</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1366/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_21_at_11_37_27_AM_png_3a0152bdf1.webp" alt="MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits" width="1366" height="128"><figcaption>MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits</figcaption></figure>The approval is <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newswire.ca/news-releases/health-canada-approves-keytruda-r-for-the-treatment-of-adult-patients-with-figo-2014-stage-iii-iva-cervical-cancer-in-combination-with-chemoradiotherapy-crt-1-810218043.html">based</a> on data from the late-stage trial. The data demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients randomized to Keytruda in combination with CRT compared with patients randomized to placebo plus CRT. The trial enrolled 1,060 newly diagnosed patients.Cervical cancer forms in the cells lining the cervix, which is the lower part of the uterus. In 2024 alone, it was estimated that there were approximately 1,600 women diagnosed with cervical cancer and an estimated 400 deaths as a result of the disease, as per data from the Canadian Cancer Society.Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas.Meanwhile, Merck will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. Analysts on average expect the company to report earnings per share of $2.02, down from $2.28 per share in the corresponding quarter of 2024.Quarterly revenue is expected to be $15.86 billion, down from the $16.11 billion reported in the corresponding period of 2024.On Stocktwits, a user expressed optimism about the stock in light of the company’s restructuring plan, upcoming trial results, and solid financial position.<stembedurl>https://stocktwits.com/jjokerst/message/621710390</stembedurl>Another, however, sounded skeptical about the overall pharmaceutical and medical technology industry.<a href="https://stocktwits.com/YouOnlyLiveTwice/message/621754509">https://stocktwits.com/YouOnlyLiveTwice/message/621754509</a>Keytruda is Merck’s blockbuster cancer drug. In the three months through the end of March, Keytruda sales increased 4% to $7.2 billion, driven by a rise in global uptake in earlier-stage indications and continued strong demand worldwide.Through full year 2024, Keytruda total sales were $29.48 billion, accounting for about 46% of the company’s total sales.MRK stock is down 20% this year and approximately 37% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-sees-28-percent-slide-in-chatter-over-past-week/ch8kz4ZR5qy">Tesla Stock Sees 28% Slide In Retail Chatter Over Past Week Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided

Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas. 

The U.S. Food and Drug Administration may reportedly fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other countries.FDA Commissioner Marty Makary floated the idea in an <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-11/fda-offers-to-trade-faster-drug-reviews-for-lower-us-prices">interview</a> on Bloomberg Television. Makary said that price adjustments may give companies another way to obtain “national priority vouchers” under the program announced last month.As part of the <a href="https://stocktwits.com/news-articles/markets/equity/fda-aims-to-reduce-drug-application-review-time-with-new-voucher-program/chlp5PzRRce">program</a>, the FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten the review time from approximately 10-12 months to one or two months after the company submits its final drug application.According to the initial plan, the agency will distribute a limited number of vouchers to companies aligned with the U.S.’ national priorities in the first year, the FDA stated, without naming any specific companies.“We can issue a national priority review voucher for companies that are promising to equalize the price” between the US and what other foreign countries pay, Makary said.“We want to incentivize good behavior in the marketplace, and these priority vouchers are worth a lot of money,” he added while noting that the program could be used as a means to even out drug prices with those currently charged in places like Europe.Trump <a href="https://stocktwits.com/news-articles/markets/equity/merck-pfizer-eli-lilly-stocks-rebound-as-trump-targets-drug-costs-with-new-executive-order/chiN18ERbmL">signed</a> an executive order in May intended to match U.S. drug prices with those of other developed countries in order to lower domestic healthcare costs.“The United States has less than five percent of the world’s population and yet funds around three-quarters of global pharmaceutical profits,” Trump said.“Americans will no longer be forced to pay almost three times more for the exact same medicines, often made in the exact same factories. As the largest purchaser of pharmaceuticals, Americans should get the best deal.”Makary, on Friday, did not detail how drugmakers have to adjust prices to qualify for a voucher, Bloomberg said. The report added that it is also unclear how much of an impact the vouchers would have and that the FDA has typically avoided entering drug pricing in the U.S.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/mink-therapeutics-patient-received-full-remission-in-testicular-cancer-with-investigational-cell-therapy/ch8cWyDR5Zt">MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report

FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Invesco Capital Management LLC - Invesco Pharmaceuticals ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$95.12
Prev Close	$94.95
Open	$95.12
Dividend Yield	N/A
50-Day Moving Average	$92.89
Beta	N/A
Avg. Volume	5,109.38
PE Ratio	N/A

52-Week High	$96.00
52-Week Low	$72.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PJP
Invesco Dynamic Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PJP News

PJPInvesco Dynamic Pharmaceuticals ETF